Scaffold-Based Tissue Engineering – From bench to bedside back to bench
Find out more about subscribing to add all events.
Scaffold-Based Tissue Engineering – From bench to bedside back to bench
Mon, 30/09/2019 - 15:00 to 16:00
Location:
Speaker:
Dietmar Hutmacher
Affiliation:
Queensland University of Technology (Brisbane, Australia)
Synopsis:
The role of Bone Engineering in the field of Regenerative Medicine has been the topic of substantial research over the past two decades. Technological advances have improved orthopaedic implants and surgical techniques for bone reconstruction. However, improvements in surgical techniques to reconstruct bone have been limited by the paucity of autologous materials available and donor site morbidity. Recent advances in the development of biomaterials have provided attractive alternatives to bone grafting expanding the surgical options for restoring the form and function of injured bone. Specifically, novel bioactive (second generation) biomaterials have been developed that are characterised by controlled action and reaction to the host tissue environment, whilst exhibiting controlled chemical breakdown and resorption with an ultimate replacement by regenerating tissue. Future generations of biomaterials (third generation) are designed to be not only osteoconductive but also osteoinductive, i.e. to stimulate regeneration of host tissues by combining tissue engineering and in situ tissue regeneration methods with a focus on novel applications. These techniques will lead to novel possibilities for tissue regeneration and repair. At present, tissue engineered constructs that may find future use as bone grafts for complex skeletal defects, whether from post-traumatic, degenerative, neoplastic or congenital/developmental “origin” require osseous reconstruction to ensure structural and functional integrity. Engineering functional bone using combinations of cells, scaffolds and bioactive factors is a promising strategy and a particular feature for future development in the area of hybrid materials which are able to exhibit suitable biomimetic and mechanical properties.
This talk reviews the mayor current strategies in challenging bone engineering applications from a basic science perspective as well as from a clinical angle. Examples of the studies using biodegradable composite scaffolds in combination with bone morphogentic growth factors (BMP-2, BMP-7) and scaffolds in combination mesencymal precursor cells in thoroughly characterized and validated preclinical animal models will be presented. This talk will discuss the state of the art in this field and what we can expect from future generations of bone regeneration concepts.
Biography:
Prof Hutmacher is a biomedical engineer, an educator, an inventor, and a creator of new intellectual property opportunities. He directs the Centre for Regenerative Medicine and the ARC Training Centre in Additive Biomanufacturing at Queensland University of Technology (Brisbane, Australia), leading a multidisciplinary team of researchers including engineers, cell biologists, polymer chemists, clinicians, and veterinary surgeons. Prof Hutmacher is an internationally recognized leader in the fields of biomaterials, tissue engineering and regenerative medicine, with expertise in commercialization. He has translated a bone tissue engineering concept from the laboratory through to clinical application involving in vitro experiments, in vivo preclinical animal studies, and ultimately, clinical trials. His recent research efforts have resulted in traditional scientific/academic outputs as well as pivotal commercialisation outcomes. His pre-eminent international standing and impact on the field are illustrated by his publication record (more than 300 journal articles, edited 14 books, 70 book chapters and some 500 conference papers) and citation record (Google Scholar: more than 45,000 citations, h-index of 101 ).
Institute:
Related Documents:
